Bayer ups peak sales forecast for Nubeqa to over €3 billion
Bayer beantragt breiteren Einsatz von Krebsmittel Nubeqa
BAYER: U.S. FDA Approves Addition of Overall Survival and Other Secondary Endpoint Data to NUBEQA® (darolutamide) Prescribing Information | FDA Reporter
Bayer projects $3B sales potential each for Kerendia, Nubeqa
Bayer's Nubeqa nabbed a second prostate cancer indication
FDA approves Bayer's Nubeqa® (darolutamide), a new treatment for men with non-metastatic castration-resistant prostate cancer
NUBEQA® | Bayer Vital GmbH Deutschland
NUBEQA® (darolutamide) Patient Assistance and Support
Nubeqa Tablet: View Uses, Side Effects, Price and Substitutes | 1mg